Progressive Supranuclear Palsy Therapeutics Pipeline to Develop More Drugs as Small Molecule: P&S Market Research

NEW YORK, March 27, 2018 -- According to a new research report titled “Progressive Supranuclear Palsy (PSP) Therapeutics Pipeline Analysis, 2017” published by P&S Market Research, PSP currently exhibits growing pipeline 14 drug candidates.

Request for Sample Copy of this Research Report: https://www.psmarketresearch.com/market-analysis/psp-pipeline-analysis/report-sample

The study analyzed that PSP therapeutics pipeline comprises approximately 14 drug candidates in different stages of development. The exact cause of PSP is unknown, but it has been observed that PSP is the accumulation of abnormal deposits of the tau protein in nerve cells in the brain, and eventual toxicity in nerve cells in the brain stem. The appearance of deposits of the microtubule-associated tau protein termed ‘neurofibrillary tangles’ is a common feature of tauopathies and development of progressive supranuclear palsy.

According to the research findings, most of the drug candidates in PSP therapeutics pipeline are being developed as small molecule agents. Also, majority of the pipeline drug candidates are being developed using the oral route of administration.

Browse Full Report with detailed TOC on “Progressive Supranuclear Palsy Therapeutics Pipeline Analysis” at: https://www.psmarketresearch.com/market-analysis/psp-pipeline-analysis

Many companies are more focused on developing their drug candidate’s as small molecule, since small molecule can easily pass through the blood brain barrier due to their low molecular weight and small size.

In April 2017, Biogen Inc. entered into an exclusive worldwide license agreement with Bristol-Myers Squibb Company to develop and commercialize BMS-986168, a Phase II investigational medicine for the treatment of Alzheimer’s disease (AD) and PSP. Some of the key players developing drugs for the treatment of progressive supranuclear palsy include AbbVie Inc., Biogen Inc., Asceneuron SA, Alzprotect SAS and others.

More Reports Published by P&S Market Research

T-Cell Immunotherapy Pipeline Analysis - https://www.psmarketresearch.com/market-analysis/t-cell-immunotherapy-pipeline-analysis

Estrogen Receptor-Positive Breast Cancer Pipeline Analysis - https://www.psmarketresearch.com/market-analysis/estrogen-receptor-positive-breast-cancer-pipeline-analysis

About P&S Market Research

P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.

As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.

Contact:
P&S Market Research

347, 5th Ave. #1402

New York City, NY - 10016

Toll-free: +1-888-778-7886 (USA/Canada)

Email: [email protected]

Web: https://www.psmarketresearch.com

Connect with us: LinkedIn | Twitter | Google + | Facebook